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Recommended Pediatric Immunization Schedules — United States - 2015
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years – United States, 2015.  
(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). 
These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. 
To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded.
Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos 19–23 mos 2-3 yrs 4-6 yrs 7-10 yrs 11-12 yrs 13–15 yrs 16–18 yrs
Hepatitis B1  (HepB)
Rotavirus2  (RV) RV1 (2-dose 
series); RV5 (3-dose series)
Diphtheria, tetanus, & acellular 
pertussis3  (DTaP: <7 yrs)
Tetanus, diphtheria, & acellular 
pertussis4  (Tdap: >7 yrs)
Haemophilus influenzae type b5 
(Hib)
Pneumococcal conjugate6 
(PCV13)
Pneumococcal polysaccharide6 
(PPSV23)
Inactivated poliovirus7 
(IPV: <18 yrs)
Influenza8  (IIV; LAIV)  2 doses for 
some: See footnote 8
Measles, mumps, rubella9  (MMR)
Varicella1 0  (VAR)
Hepatitis A1 1  (HepA) 
Human papillomavirus1 2  (HPV2: 
females only; HPV4: males and 
females)
Meningococcal1 3  (Hib-MenCY  
> 6 weeks; MenACWY-D >9 mos; 
MenACWY-CRM ≥ 2 mos) 
Booster1st doseSee footnote 13
(3-dose 
series) 
Annual vaccination (LAIV or 
IIV) 1 or 2 dosesAnnual vaccination (IIV only) 1 or 2 doses
(Tdap)
See 
footnote 22
nd dose1st dose
4th dose3rd dose2nd dose1st dose
2-dose series, See footnote 11
4th dose3rd dose2nd dose1st dose
2nd dose1st dose
3rd or 4th dose, 
See footnote 5
See 
footnote 52
nd dose1st dose
2nd dose1st dose
5th dose4th dose3rd dose2nd dose1st dose
3rd dose2nd dose1st dose
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
This schedule includes recommendations in effect as of January 1, 2015. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and 
feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee 
on Immunization Practices (ACIP) statement for detailed recommendations, available online at http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Clinically significant adverse events that follow 
vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online (http://www.vaers.hhs.gov) or by telephone (800-822-7967). Suspected cases of vaccine-preventable 
diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online  
(http://www.cdc.gov/vaccines/recs/vac-admin/contraindications.htm) or by telephone (800-CDC-INFO [800-232-4636]).
This schedule is approved by the Advisory Committee on Immunization Practices (http//www.cdc.gov/vaccines/acip), the American Academy of Pediatrics (http://www.aap.org), the American Academy of 
Family Physicians (http://www.aafp.org), and the American College of Obstetricians and Gynecologists (http://www.acog.org).
Not routinely 
recommended
Range of recommended ages for 
certain high-risk  groups
Range of recommended 
ages for all children
Range of recommended ages 
for catch-up immunization
Range of recommended ages during 
which catch-up is encouraged and for 
certain high-risk groups
Annual vaccination (LAIV or IIV)  
1 dose only
See footnote 9
FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind —United States, 2015.
The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section 
appropriate for the child’s age. Always use this table in conjunction with Figure 1 and the footnotes that follow.
Children age 4 months through 6 years
Vaccine
Minimum 
Age for 
Dose 1
Minimum Interval Between Doses
Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5
Hepatitis B1 Birth 4 weeks
8 weeks 
and at least 16 weeks after first dose. 
Minimum age for the final dose is 24 weeks.
Rotavirus2 6 weeks 4 weeks 4 weeks2
Diphtheria, tetanus, and acel-
lular pertussis3 6 weeks 4 weeks 4 weeks 6 months 6 months
3
Haemophilus influenzae 
type b5 6 weeks
4 weeks 
if first dose was administered before the 1st birthday.
8 weeks (as final dose) 
if first dose was administered at age 12 through 14 months.
No further doses needed if first dose was administered at age 15 
months or older.
4 weeks5 
if current age is younger than 12 months and first dose was administered at 
younger than age 7 months, and at least 1 previous dose was PRP-T (ActHib, 
Pentacel) or unknown.
8 weeks 
and age 12 through 59 months (as final dose)5 
•	 if current age is younger than 12 months  
and first dose was administered at age 7 through 11 months; 
OR
•	 if current age is 12 through 59 months  
and first dose was administered before the 1st birthday, and second dose 
administered at younger than 15 months;  
OR
•	 if both doses were PRP-OMP (PedvaxHIB; Comvax)  
and were administered before the 1st birthday.
No further doses needed 
if previous dose was administered at age 15 months or older.
8 weeks (as final dose) 
This dose only necessary for children age 12 through 59 months 
who received 3 doses before the 1st birthday.
Pneumococcal6 6 weeks
4 weeks 
if first dose administered before the 1st birthday.
8 weeks (as final dose for healthy children)
if first dose was administered at the 1st birthday or after.
No further doses needed 
for healthy children if first dose administered at age 24 months or 
older.
4 weeks 
if current age is younger than 12 months and previous dose given at <7months 
old.
8 weeks (as final dose for healthy children) 
if previous dose given between 7-11 months (wait until at least 12 months old); 
OR
if current age is 12 months or older and at least 1 dose was given before age 
12 months.
No further doses needed for healthy children if previous dose administered at 
age 24 months or older.
8 weeks (as final dose) 
This dose only necessary for children aged 12 through 59 months 
who received 3 doses before age 12 months or for children at high 
risk who received 3 doses at any age.
Inactivated poliovirus7 6 weeks 4 weeks7 4 weeks7 6 months7 (minimum age 4 years for final dose).
Meningococcal13 6 weeks 8 weeks13 See footnote 13 See footnote 13
Measles, mumps, rubella9 12 months 4 weeks
Varicella10 12 months 3 months
Hepatitis A11 12 months 6 months
Children and adolescents age 7 through 18 years
Tetanus, diphtheria; tetanus, 
diphtheria, and acellular 
pertussis4
7 years4 4 weeks 
4 weeks 
if first dose of DTaP/DT was administered before the 1st birthday. 
6 months (as final dose) 
if first dose of DTaP/DT was administered at or after the 1st birthday.
6 months if first dose of DTaP/DT  was administered before the 1st 
birthday.
Human papillomavirus12 9 years Routine dosing intervals are recommended.12
Hepatitis A11
Not  
applicable
(N/A)
6 months
Hepatitis B1 N/A 4 weeks 8 weeks and at least 16 weeks after first dose.
Inactivated poliovirus7 N/A 4 weeks 4 weeks7 6 months7
Meningococcal13 N/A 8 weeks13 
Measles, mumps, rubella9 N/A 4 weeks
Varicella10 N/A 3 months if younger than age 13 years. 4 weeks if age 13 years or older.
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
CR-010648    3/15
For more information visit:
www.scdhec.gov/scimmunize
Footnotes — Recommended immunization schedule for persons aged 0 through 18 years—United States, 2015  
For further guidance on the use of the vaccines mentioned below, see: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
•	 For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at 
http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
•	 For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
•	 Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not 
be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see MMWR, 
General Recommendations on Immunization and Reports / Vol. 60 / No. 2; Table 1. Recommended and minimum ages and intervals between vaccine doses available online at  
http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.
•	 Information on travel vaccine requirements and recommendations is available at http://wwwnc.cdc.gov/travel/destinations/list.
•	 For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, “Vaccination of persons with primary and secondary immunodeficiencies,” in General Recommendations on 
Immunization (ACIP), available at http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.; and American Academy of Pediatrics. “Immunization in Special Clinical Circumstances,” in Pickering LK, Baker CJ, 
Kimberlin DW, Long SS eds. Red Book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics.
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination: 
At birth:
•	 Administer monovalent HepB vaccine to all newborns before hospital discharge.
•	 For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 
0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested 
for HBsAg and antibody to HBsAg (anti-HBs) 1 to 2 months after completion of the HepB series at age 9 
through 18 months (preferably at the next well-child visit).
•	 If mother’s HBsAg status is unknown, within 12 hours of birth administer HepB vaccine regardless of birth 
weight. For infants weighing less than 2,000 grams, administer HBIG in addition to HepB vaccine within 
12 hours of birth. Determine mother’s HBsAg status as soon as possible and, if mother is HBsAg-positive, 
also administer HBIG for infants weighing 2,000 grams or more as soon as possible, but no later than age 
7 days.
Doses following the birth dose:
•	 The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be 
used for doses administered before age 6 weeks.
•	 Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a 
schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. See Figure 2.
•	 Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks), administer 
the third dose at least 8 weeks after the second dose AND at least 16 weeks after the first dose. The final 
(third or fourth) dose in the HepB vaccine series should be administered no earlier than age 24 weeks.
•	 Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing 
HepB is administered after the birth dose. 
Catch-up vaccination:
•	 Unvaccinated persons should complete a 3-dose series.
•	 A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for 
use in children aged 11 through 15 years. 
•	 For other catch-up guidance, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] and  
RV5 [RotaTeq])
Routine vaccination:
Administer a series of RV vaccine to all infants as follows: 
1. If Rotarix is used, administer a 2-dose series at 2 and 4 months of age. 
2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months. 
3. If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the series, a total of 
3 doses of RV vaccine should be administered. 
Catch-up vaccination:
•	 The maximum age for the first dose in the series is 14 weeks, 6 days; vaccination should not be initiated 
for infants aged 15 weeks, 0 days or older.
•	 The maximum age for the final dose in the series is 8 months, 0 days.
•	 For other catch-up guidance, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum 
age: 6 weeks. Exception: DTaP-IPV [Kinrix]: 4 years)
Routine vaccination:
•	 Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years.  
The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed 
since the third dose.  However, the fourth dose of DTaP need not be repeated if it was administered at 
least 4 months after the third dose of DTaP.
3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine (cont’d)
Catch-up vaccination:
•	 The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.
•	 For other catch-up guidance, see Figure 2.
4. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum 
age: 10 years for both Boostrix and Adacel)
Routine vaccination: 
•	 Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years.
•	 Tdap may be administered regardless of the interval since the last tetanus and diphtheria toxoid-
containing vaccine.
•	 Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 
through 36 weeks’ gestation) regardless of time since prior Td or Tdap vaccination. 
Catch-up vaccination:
•	 Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap 
vaccine as 1 dose (preferably the first) in the catch-up series; if additional doses are needed, use Td 
vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series, an 
adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be 
administered instead 10 years after the Tdap dose.
•	 Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by 
tetanus and diphtheria toxoid (Td) booster doses every 10 years thereafter.
•	 Inadvertent doses of DTaP vaccine:
 - If administered inadvertently to a child aged 7 through 10 years may count as part of the catch-up 
series. This dose may count as the adolescent Tdap dose, or the child can later receive a Tdap booster 
dose at age 11 through 12 years.
 - If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted 
as the adolescent Tdap booster. 
•	 For other catch-up guidance, see Figure 2.
5. Haemophilus influenzae type b (Hib) conjugate vaccine.  (Minimum age:  6 weeks 
for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel) and Hib-MenCY (MenHibrix)], PRP-OMP 
[PedvaxHIB or COMVAX], 12 months for PRP-T [Hiberix]) 
Routine vaccination:
•	 Administer a 2- or 3-dose Hib vaccine primary series and a booster dose (dose 3 or 4 depending on 
vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series.
•	 The primary series with ActHIB, MenHibrix, or Pentacel consists of 3 doses and should be administered at 
2, 4, and 6 months of age. The primary series with PedvaxHib or COMVAX consists of 2 doses and should 
be administered at 2 and 4 months of age; a dose at age 6 months is not indicated.
•	 One booster dose (dose 3 or 4 depending on vaccine used in primary series) of any Hib vaccine should 
be administered at age 12 through 15 months. An exception is Hiberix vaccine. Hiberix should only be 
used for the booster (final) dose in children aged 12 months through 4 years who have received at least 1 
prior dose of Hib-containing vaccine.
•	 For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, 
please refer to the meningococcal vaccine footnotes and also to MMWR February 28, 2014 / 63(RR01);1-
13, available at http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.
Footnotes — Recommended immunization schedule for persons aged 0 through 18 years—United States, 2015  
For further guidance on the use of the vaccines mentioned below, see: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional informatio
•	 For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at 
http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
•	 For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
•	 Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not 
be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see MMWR, 
General Recomme d ions on Immunization and Reports / Vol. 60 / No. 2; Table 1. Recommended and minimum ag s and intervals between vaccine doses avail ble o line at  
http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.
•	 Information on travel vaccine requirements and recommendations is available at http://wwwnc.cdc.gov/travel/destinations/list.
•	 For vaccination of persons with primary and secon ary immunodeficiencies, see Table 13, “Vaccination of persons with primary and secondary immuno eficiencies,” in G neral Recommendations on 
Immunization (ACIP), available at http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.; and American Academy of Pediatrics. “Immunization in Special Clinical Circumstances,” in Pickering LK, Baker CJ, 
Kimberlin DW, Long SS eds. Red Book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics.
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination: 
At birth:
•	 Administer monovalent HepB vaccine to all newborns before hospital discharge.
•	 For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 
0.5 mL of hepatitis B immu e globulin (HBIG) within 12 hours of birth. These infants should be tested 
for HBsAg and antibody to HBsAg (anti-HBs) 1 to 2 months after completion of the HepB series at age 9 
through 18 months (preferably at the next well-child visit).
•	 If mother’s HB Ag status is unknown, within 12 hours of birth administer HepB vaccine regardless of birth 
weight. For infants weighing less than 2,000 grams, administer HBIG in addition to HepB vaccine within 
12 hours of birth. Determine mother’s HBsAg status as soon as possible and, if mother is HBsAg-positive, 
also ad inis er HBIG for infants weighing 2,000 grams or more as soon as possible, but no late  an age 
7 days.
Doses following the birth dose:
•	 The second dose should be administered at ag  1 or 2 month . Monovalent HepB vaccine sh uld be
used for doses administered before age 6 weeks.
•	 Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a 
schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. See Figure 2.
•	 Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks), administer 
the third dose at least 8 weeks after the second dose AND at least 16 weeks after the first dose. The final 
(third or fourth) dose in the HepB vaccine series should be administered no earlier than age 24 weeks.
•	 Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing 
HepB is administered after the birth dose. 
Catch-up vaccination:
•	 Unvaccinated persons should complete a 3-dose series.
•	 A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for 
use in children aged 11 through 15 years. 
•	 For other catch-up guidance, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] and  
RV5 [RotaTeq])
Routine vaccination:
Administer a series of RV vaccine to all infants as follows: 
1. If Rotarix is used, admi ister a 2- ose series at 2 and 4 months of age. 
2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months. 
3. If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the series, a total of 
3 doses of RV vaccine should be administered. 
Catch-up vaccination:
•	 The maximum age for the first dose in the series is 14 weeks, 6 days; vaccination should not be initiated 
for infants aged 15 weeks, 0 days or older.
•	 The maximum age for the final dose in the series is 8 months, 0 days.
•	 For other catch-up guidance, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum 
age: 6 weeks. Exception: DTaP-IPV [Kinrix]: 4 years)
Routine vaccination:
•	 Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years.  
The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed 
since the third dose.  However, the fourth dose of DTaP need not be repe ted if it was administered at 
least 4 months after the third dose of DTaP.
3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine (cont’d)
Catch-up vaccination:
•	 The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.
•	 For other catch-up guidance, see Figure 2.
4. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum 
age: 10 years for both Boostrix and Adacel)
Routine v ccination: 
•	 Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years.
•	 Tdap may be administered regardless of the interval since the last tetanus and diphtheri  toxoid-
containing vaccine.
•	 Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 
through 36 weeks’ gestation) regardless of time since prior Td or Tdap vaccination. 
Catch-up vaccination:
•	 Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap 
vaccine as 1 dose (preferably the first) in the catch-up series; if additional doses are needed, use Td 
vaccine. For childre  7 through 10 years who receive a dose of Tdap as part of the catch-up series, an 
adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be 
administered instead 10 years after the Tdap dose.
•	 Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by 
tetanus and diphtheria toxoid (Td) booster doses every 10 years thereafter.
•	 Inadvertent doses of DTaP vaccine:
 - If administered inadvertently to a child aged 7 through 10 years may count as part of the catch-up 
series. This dose may count as the adolescent Tdap dose, or the child can lat r receive a Tdap booster 
dose at age 11 through 12 years.
 - If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted 
as the adolescent Tdap booster. 
•	 For other catch-up guidance, see Figure 2.
5. Haemophilus influenzae type b (Hib) conjugate vaccine.  (Minimum age:  6 weeks 
for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel) and Hib-MenCY (MenHibrix)], PRP-OMP 
[PedvaxHIB or COMVAX], 12 months for PRP-T [Hiberix]) 
R utine vaccination:
•	 Administer a 2- or 3-dose Hib vaccine primary series and a booster dose (dose 3 or 4 depending on 
vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series.
•	 The primary series with ActHIB, MenHibrix, or Pentacel consists of 3 doses and should be administered at 
2, 4, and 6 months of age. The primary series with PedvaxHib or COMVAX consists of 2 doses and should 
be administered at 2 and 4 months of age; a dose at age 6 months is not indicated.
•	 One booster dose (dose 3 or 4 depending on vaccine used in primary series) of any Hib vaccine should 
be administered at age 12 through 15 months. An exception is Hiberix vaccine. Hiberix should only be 
used for the booster (final) dose in children aged 12 months through 4 years who have received at least 1 
prior dose of Hib-containing vaccine.
•	 For recommendations on the use of MenHibrix in patients at increased risk f r meningococcal diseas , 
please refer to the meningococcal vaccine footnotes and also to MMWR February 28, 2014 / 63(RR01);1-
13, available at http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.
Footnotes — Recommended immunization schedule for persons aged 0 through 18 years—United States, 2015  
For further guidance on the use of the vaccines mentioned below, see: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
•	 For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at 
http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
•	 For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
•	 Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not 
be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see MMWR, 
General Recommendations on Immunization and Reports / Vol. 60 / No. 2; Table 1. Recommended and minimum ages and intervals between vaccine dos s available online at  
http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.
•	 Information on travel vaccine requirements and recommendations is available at http://wwwnc.cdc.gov/travel/destinations/list.
•	 For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, “Vaccination of persons with primary and secondary immunodeficiencies,” in General Recommendations on 
Immunization (ACIP), available at http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.; and American Academy of Pediatrics. “Immunizati n in Special Clinical Circums ances,” in Pickering LK, Baker CJ, 
Kimberlin DW, Long SS eds. Red Book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics.
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination: 
At birth:
•	 Administer monovalent HepB vaccine to all newborns before hospital discharge.
•	 For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 
0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested 
for HBsAg and antibody to HBsAg (anti-HBs) 1 to 2 months after completion of the HepB series at age 9 
through 18 months (preferably at the next well-child visit).
•	 If mother’s HBsAg status is unknown, within 12 hours of birth administer HepB vaccine regardless of birth 
weight. For infants weighing less than 2,000 grams, administer HBIG in addition to HepB vaccine within 
12 hours of birth. Determine mother’s HBsAg status as soon as possible and, if mother is HBsAg-positive, 
also administer HBIG for infants weighing 2,000 grams or more as soon as possible, but no later than age 
7 days.
Doses following the birth dose:
•	 The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be 
used for doses administered before age 6 weeks.
•	 Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a 
schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. See Figure 2.
•	 Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks), administer 
the third dose at least 8 weeks after the second dose AND at least 16 weeks after the first dose. The final 
(third or fourth) dose in the HepB vaccine series should be administered no earlier than age 24 weeks.
•	 Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing 
HepB is administered after the birth dose. 
Catch-up vaccination:
•	 Unvaccinated persons should complete a 3-dose series.
•	 A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for 
use in children aged 11 through 15 years. 
•	 For other catch-up guidance, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] and  
RV5 [RotaTeq])
Routine vaccination:
Administer a series of RV vaccine to all infants as follows: 
1. If Rotarix is used, administer a 2-dose series at 2 and 4 months of age. 
2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months. 
3. If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the series, a total of 
3 doses of RV vaccine should be administered. 
Catch-up vaccination:
•	 The maximum age for the first dose in the series is 14 weeks, 6 days; vaccination should not be initiated 
for infants aged 15 weeks, 0 days or older.
•	 The maximum age for the final dose in the series is 8 months, 0 days.
•	 For other catch-up guidance, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum 
age: 6 weeks. Exception: DTaP-IPV [Kinrix]: 4 years)
Routine vaccination:
•	 Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years.  
The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed 
since the third dose.  However, the fourth dose of DTaP need not be repeated if it was administered at 
least 4 months after the third dose of DTaP.
3. Diphtheria and e anus toxoids and acellular pertussis (DTaP) vaccine (cont’d)
Catch-up vaccination:
•	 The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.
•	 For other catch-up guidance, see Figure 2.
4. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum 
age: 10 years for both Boostrix and Adacel)
Routine vaccination: 
•	 Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years.
•	 Tdap may be adm nistered re ardless of th  interval since the last t tanus and diphtheria toxoid-
containing vaccine.
•	 Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 
throug  36 weeks’ gestation) regardless of time since prior Td or Tdap vaccination. 
Catch-up vaccination:
•	 Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap 
vaccine as 1 dose (preferably the first) in the catch-up series; if additional doses are needed, use Td 
vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series, an 
adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be 
administered instead 10 years after the Tdap dose.
•	 Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by 
tetanus and diphtheria toxoid (Td) booster doses every 10 years thereafter.
•	 Inadvertent doses of DTaP vaccine:
 - If administered ina vertently to a child ged 7 through 10 ye r  m y count as part of the catch-up 
series. This dose may count as the adolescent Tdap dose, or the child can later receive a Tdap booster 
dose at age 11 through 12 years.
 - If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted 
as the adolescent Tdap booster. 
•	 For other catch-up guidance, see Figure 2.
5. Haemophilus influenzae type b (Hib) conjugate vaccine.  (Minimum age:  6 weeks 
for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel) and Hib-MenCY (MenHibrix)], PRP-OMP 
[PedvaxHIB or COMVAX], 12 months for PRP-T [Hiberix]) 
Routine vaccination:
•	 Administer a 2- or 3-dose Hib vaccine primary series and a booster dose (dose 3 or 4 depending on 
vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series.
•	 The primary series with ActHIB, MenHibrix, or Pentacel consists of 3 doses and should be administered at 
2, 4, and 6 months of age. The primary series with PedvaxHib or COMVAX consists of 2 doses and should 
be administered at 2 and 4 months of age; a dose at age 6 months is not indicated.
•	 One booster dose (dose 3 or 4 depending on vaccine used in primary series) of any Hib vaccine should 
be administered at age 12 through 15 months. An exception is Hiberix vaccine. Hiberix should only be 
used for the booster (final) dose in children aged 12 months through 4 years who have received at least 1 
prior dose of Hib-containing vaccine.
•	 For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, 
please refer to the meningococcal vaccine footnotes and also to MMWR February 28, 2014 / 63(RR01);1-
13, available at http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.5. Haemophilus influenzae type b (Hib) conjugate vaccine (cont’d)
Catch-up vaccination:
•	 If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 
weeks after dose 1, regardless of Hib vaccine used in the primary series.
•	 If both doses were PRP-OMP (PedvaxHIB or COMVAX), and were administered before the first birthday, 
the third (and final) dose should be administered at age 12 through 59 months and at least 8 weeks after 
the second dose.
•	 If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 
weeks later and a third (and final) dose at age 12 through 15 months or 8 weeks after second dose, 
whichever is later.
•	 If first dose is administered before the first birthday and second dose administered at younger than 15 
months, a third (and final) dose should be given 8 weeks later.
•	 For unvaccinated children aged 15 months or older, administer only 1 dose.
•	 For other catch-up guidance, see Figure 2. For catch-up guidance related to MenHibrix, please see the 
meningococcal vaccine footnotes and also MMWR February 28, 2014 / 63(RR01);1-13, available at  
http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.
Vaccination of persons with high-risk conditions: 
•	 Children aged 12 through 59 months who are at increased risk for Hib disease, including chemotherapy 
recipients and those with anatomic or functional asplenia (including sickle cell disease), human  
immunodeficiency virus (HIV ) infection, immunoglobulin deficiency, or early component complement  
deficiency, who have received either no doses or only 1 dose of Hib vaccine before 12 months of  age, 
should receive 2 additional doses of Hib vaccine 8 weeks apart; children who received 2 or more  doses of 
Hib vaccine before 12 months of age should receive 1 additional dose.
•	 For patients younger than 5 years of age undergoing chemotherapy or radiation treatment who received 
a Hib vaccine dose(s) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 
months following therapy completion.
•	 Recipients of hematopoietic stem cell transplant (HSCT) should be revaccinated with a 3-dose regimen 
of Hib vaccine starting 6 to 12 months after successful transplant, regardless of vaccination history; doses 
should be administered at least 4 weeks apart.
•	 A single dose of any Hib-containing vaccine should be administered to unimmunized* children and 
adolescents 15 months of age and older undergoing an elective splenectomy; if possible, vaccine should 
be administered at least 14 days before procedure.
•	 Hib vaccine is not routinely recommended for patients 5 years or older. However, 1 dose of Hib vaccine 
should be administered to unimmunized* persons aged 5 years or older who have anatomic or 
functional asplenia (including sickle cell disease) and unvaccinated persons 5 through 18 years of age 
with human immunodeficiency virus (HIV) infection.
* Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 
months of age are considered unimmunized. 
6. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23)
Routine vaccination with PCV13:
•	 Administer a 4-dose series of PCV13 vaccine at ages 2, 4, and 6 months and at age 12 through 15 months.
•	 For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV 
(PCV7), administer a single supplemental dose of 13-valent PCV (PCV13). 
Catch-up vaccination with PCV13:
•	 Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely 
vaccinated for their age.
•	 For other catch-up guidance, see Figure 2. 
Vaccination of persons with high-risk conditions with PCV13 and PPSV23:
•	 All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible.
•	 For children 2 through 5 years of age with any of the following conditions: chronic heart disease 
(particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including 
asthma if treated with high-dose oral corticosteroid therapy); diabetes mellitus; cerebrospinal fluid leak; 
cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; 
HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with 
immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin’s disease; solid organ transplantation; or congenital immunodeficiency: 
1. Administer 1 dose of PCV13 if any incomplete schedule of 3 doses of PCV (PCV7 and/or PCV13) were 
received previously.
2. Administer 2 doses of PCV13 at least 8 weeks apart if unvaccinated or any incomplete schedule of fewer 
than 3 doses of PCV (PCV7 and/or PCV13) were received previously.
3. Administer 1 supplemental dose of PCV13 if 4 doses of PCV7 or other age-appropriate complete PCV7 
series was received previously.
4. The minimum interval between doses of PCV (PCV7 or PCV13) is 8 weeks.
5. For children with no history of PPSV23 vaccination, administer PPSV23 at least 8 weeks after the most 
recent dose of PCV13.
6. Pneumococcal vaccines (cont’d)
•	 For children aged 6 through 18 years who have cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated 
with treatment with immunosuppressive drugs or radiation therapy, including malignant  neoplasms, 
leukemias, lymphomas, and Hodgkin’s disease; generalized malignancy; solid organ transplantation; or 
multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previously, administer 1 dose of PCV13 now and 1 dose 
of PPSV23 at least 8 weeks later.
2. If PCV13 has been received previously but PPSV23 has not, administer 1 dose of PPSV23 at least 8 weeks 
after the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, administer 1 dose of PCV13 at least 8 weeks after the 
most recent dose of PPSV23.
•	 For children aged 6 through 18 years with chronic heart disease (particularly cyanotic congenital heart 
disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral 
corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received 
PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be 
administered at least 8 weeks after any prior PCV13 dose.
•	 A single revaccination with PPSV23 should be administered 5 years after the first dose to children with 
sickle cell disease or other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated 
with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, 
leukemias, lymphomas, and Hodgkin’s disease; generalized malignancy; solid organ transplantation; or 
multiple myeloma.
7. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
Routine vaccination:
•	 Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the 
series should be administered on or after the fourth birthday and at least 6 months after the previous dose.
Catch-up vaccination:
•	 In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk 
of imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
•	 If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 
through 6 years and at least 6 months after the previous dose.
•	 A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months 
after the previous dose.
•	 If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless 
of the child’s current age. IPV is not routinely recommended for U.S. residents aged 18 years or older.
•	 For other catch-up guidance, see Figure 2.
8. Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 
2 years for live, attenuated influenza vaccine [LAIV]) 
Routine vaccination:
•	 Administer influenza vaccine annually to all children beginning at age 6 months. For most healthy, 
nonpregnant persons aged 2 through 49 years, either LAIV or IIV may be used. However, LAIV should NOT 
be administered to some persons, including 1) persons who have experienced severe allergic reactions 
to LAIV, any of its components, or to a previous dose of any other influenza vaccine; 2) children 2 through 
17 years receiving aspirin or aspirin-containing products; 3) persons who are allergic to eggs; 4) pregnant 
women; 5) immunosuppressed persons; 6) children 2 through 4 years of age with asthma or who had 
wheezing in the past 12 months; or 7) persons who have taken influenza antiviral medications in the 
previous 48 hours. For all other contraindications and precautions to use of LAIV, see MMWR August 15, 
2014 / 63(32);691-697 [40 pages] available at  
http://www.cdc.gov/mmwr/pdf/wk/mm6332.pdf. 
For children aged 6 months through 8 years:
•	 For the 2014-15 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving 
influenza vaccine for the first time. Some children in this age group who have been vaccinated previously 
will also need 2 doses. For additional guidance, follow dosing guidelines in the 2014-15 ACIP influenza 
vaccine recommendations, MMWR August 15, 2014 / 63(32);691-697 [40 pages] available at http://www.
cdc.gov/mmwr/pdf/wk/mm6332.pdf.
•	 For the 2015–16 season, follow dosing guidelines in the 2015 ACIP influenza vaccine recommendations.  
For persons aged 9 years and older:
•	 Administer 1 dose.
For further guidance on the use of the vaccines mentioned below, see: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.
5. Haemophilus influenza  type b (Hib) conjugate vaccine (cont’d)
Catch-up vaccination:
•	 If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 
week  after dose 1, regardless of Hib vacci e used in the primary serie .
•	 If both doses were PRP-OMP (PedvaxHIB or COMVAX), and were administered b for  the first birth ay, 
the third (and final) dose should be administered at age 12 through 59 months and at least 8 we ks after 
the econd dose.
•	 If the first d se was administered at age 7 through 11 months, administer the second dose at least 4 
weeks later and a third (and final) dose at age 12 thr ugh 15 mo th  or 8 weeks aft r second dos , 
whichever is la er.
•	 If first d se is administered befor  the first birthday and second dos dministered at younger than 15 
months, a ird (and final) dose should be given 8 weeks lat r.
•	 For unvaccinated children aged 15 months or older, administer only 1 dose.
•	 For other ca ch-up guidance, see Figure 2. For catch-up guidance related to MenHibrix, please see the 
meningococcal vaccine footnote  and also MMWR February 28, 2014 / 63(RR01);1-13, availab e t  
http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.
Vaccination of persons with high-risk conditions: 
•	 Childr n aged 12 thr ugh 59 months who are at increased risk for Hib disease, including chemotherapy 
recipients and th se with anatomic or functional asplenia (including sickl  cel diseas ), human  
immunodeficiency virus (HIV ) infection, immunoglobulin deficiency, or e rly component complement  
deficiency, who have receiv d either no doses or only 1 dose of Hib vaccine before 12 onths of  age, 
should receive 2 additi nal doses of Hib vac ine 8 we ks apart; c ildren who received 2 or m re  doses of 
Hib vaccine before 12 months of age should receive 1 additional dose.
•	 For patients younger than 5 years of age undergoing chemotherapy or radiation treatment who received 
a Hib v ccine dose( ) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 
mont s following therapy completion.
•	 Recipients of hematopoietic stem cell transplant (HSCT) should be revaccinated with a 3-dose regimen 
of Hib vaccine starting 6 to 12 months after successful transplant, regardless of vaccination history; doses 
should be administered at least 4 weeks apart.
•	 A single dose of any Hib-containing vaccine should be administered to unimmunized* children and 
adolescents 15 months of age and older undergoing an elective splenectomy; if possible, vaccine should 
be a ministered at least 14 days before procedure.
•	 Hib vaccine is not routinely recommended for patients 5 years or older. However, 1 dose of Hib vaccine 
should be administered to unimmunized* persons aged 5 years or older who have anatomic or 
functional asplenia (including sickle cell disease) and unvaccinated persons 5 through 18 years of age 
with human immunodeficiency virus (HIV) infection.
* Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 
months of age are considered unimmunized. 
6. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23)
Routine vaccination with PCV13:
•	 Administer a 4-dose series of PCV13 vaccine at g s 2, 4, and 6 months and at age 12 through 15 months.
•	 For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV 
(PCV7), administer a single supplemental dose of 13-valent PCV (PCV13). 
Catch-up vaccination with PCV13:
•	 Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely 
vaccinated for their age.
•	 For other catch-up guidanc , see Figure 2. 
Vaccination of persons with high-risk conditions with PCV13 and PPSV23:
•	 All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible.
•	 For children 2 through 5 years of age with any of the following conditions: chronic heart disease 
(particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including 
asthma if treated with high-dose oral corticosteroid therapy); diabetes mellitus; cerebrospinal fluid leak; 
cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; 
HIV inf ction; chronic renal failure; nephrotic syndrom ; diseases as ociat d with treatment with 
mmunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, 
and Hodgkin’s disease; solid organ transplantation; or congenital immunodeficiency: 
1. Administer 1 dos  of PCV13 if any incomple e chedul  of 3 do es of PCV (PCV7 nd/ r PCV13) were 
received previously.
2. Administer 2 doses of PCV13 at least 8 weeks apart if unvaccinated or any incom l t  schedule of fewer 
than 3 dose  of PCV (PCV7 an /or PCV13) were receiv p eviously.
3. Administer 1 supplemental dose of PCV13 if 4 doses of PCV7 or other age-appropriate complete PCV7 
series was r ceived previously.
4. The minimum int val between doses of PCV (PCV7 or PCV13) is 8 weeks.
5. For children with no history of PPSV23 va cination, administer PPSV23 at l ast 8 weeks after the most 
recent ose of PCV13.
6. Pneumococcal vaccines (cont’d)
•	 For childre  aged 6 through 18 years who have cerebrospinal fluid leak; cochlear implant; sickle cell 
disease and ther hemoglobinopathies; anatomic r functional plenia; congeni al or acqui ed 
immunodeficiencies; HIV inf ction; chronic renal failure; nephrotic syndrome; diseases associated 
with treatment wit  immunosuppressive drugs or radiation therapy, including malignant  eoplasms, 
leukemias, lymphomas, and Hodgki ’s disease; generalized malignancy; solid organ transplantation; or 
multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previously, dminister 1 dose of PCV13 now and 1 dose 
of PPSV23 at least 8 w eks later.
2. If PCV13 has been received previously but PPSV23 has not, administer 1 dose of PPSV23 at least 8 weeks 
after the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, administer 1 dose of PCV13 at least 8 weeks after the 
most recent dose of PPSV23.
•	 For children aged 6 through 18 years with chronic heart disease (particularly cyanotic congenital heart 
disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral 
corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received 
PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be 
administered at least 8 weeks after any prior PCV13 dose.
•	 A single revaccination with PPSV23 should be administered 5 years after the first dose to children with 
sickle cell disease or other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired 
immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated 
with treatment with immunosuppressive drugs or radiation therapy, including malignant n oplasms, 
leukemias, lymphomas, and Hodgkin’s disease; generalized malignancy; solid organ transplantation; or 
multiple myeloma.
7. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
Routine vaccination:
•	 Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the 
series should be administered on or after the fourth birthday and at least 6 months after the previous dose.
Catch-up vaccination:
•	 In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk 
of imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
•	 If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 
through 6 years and at least 6 months after the previous dose.
•	 A fourth dose is not necessary if the third dose was administered at age 4 yea s or older and at least 6 months 
after the previous dose.
•	 If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless 
of the child’s current age. IPV is not routinely recommended for U.S. residents aged 18 years or ol er.
•	 For other catch-up guidance, se  Figure 2.
8. Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 
2 years for live, attenuated influenza vaccine [LAIV]) 
Routine vaccination:
•	 Administer influenza vaccine annually to all children beginning at age 6 months. For most healthy, 
nonpregnant persons aged 2 through 49 years, either LAIV or IIV may be used. However, LAIV should NOT 
be administered to some persons, including 1) persons who have experienced severe allergic reactions 
to LAIV, any of its components, or to a previous dose of any other influenz  vaccine; 2) children 2 through 
17 years receiving aspirin or aspirin-containing products; 3) persons who are allergic to eggs; 4) pregnant 
women; 5) immunosuppressed persons; 6) children 2 through 4 years of age with asthma or who had 
wheezing in the past 12 months; or 7) persons who have taken influenza antiviral medications in the 
previous 48 hours. For all other contraindications and precautions to use of LAIV, see MMWR August 15, 
2014 / 63(32);691-697 [40 pages] available at  
http://www.cdc.gov/mmwr/pdf/wk/mm6332.pdf. 
For children aged 6 months through 8 years:
•	 For the 2014-15 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving 
influenza vaccine for the first time. Some children in this age group who have been vaccinated previously 
will also need 2 doses. For additional guidance, follow dosing guidelines in the 2014-15 ACIP influenza 
vaccine recommendations, MMWR August 15, 2014 / 63(32);691-697 [40 pages] available at http://www.
cdc.gov/mmwr/pdf/wk/mm6332.pdf.
•	 For the 2015–16 season, follow dosing guidelines in the 2015 ACIP influenza vaccine recommendations.  
For persons aged 9 years and older:
•	 Administer 1 dose.
For furth  guidance on th  use of th  vaccines enti ed below, s e: http://www.cdc.gov/vac i es/hcp/acip-re /index.html.
For further gui ance on the use of the vaccines mentioned below, see: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.
9. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 months for routine 
vaccination)
Routine vaccination:
•	 Administer a 2-dose series of MMR vaccine at ages 12 through 15 months and 4 through 6 years. The 
second dose may be administered before age 4 years, provided at least 4 weeks have elapsed since the first 
dose.
•	 Administer 1 dose of MMR vaccine to infants aged 6 through 11 months before departure from the United 
States for international travel. These children should be revaccinated with 2 doses of MMR vaccine, the first 
at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the 
second dose at least 4 weeks later.
•	 Administer 2 doses of MMR vaccine to children aged 12 months and older before departure from the 
United States for international travel. The first dose should be administered on or after age 12 months and 
the second dose at least 4 weeks later.
Catch-up vaccination:
•	 Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum 
interval between the 2 doses is 4 weeks.  
10. Varicella (VAR) vaccine. (Minimum age: 12 months) 
Routine vaccination:
•	 Administer a 2-dose series of VAR vaccine at ages 12 through 15 months and 4 through 6 years. The 
second dose may be administered before age 4 years, provided at least 3 months have elapsed since the 
first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as 
valid.
Catch-up vaccination:
•	 Ensure that all persons aged 7 through 18 years without evidence of immunity (see MMWR 2007 / 56 [No. 
RR-4], available at http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf ) have 2 doses of varicella vaccine.  For 
children aged 7 through 12 years, the recommended minimum interval between doses is 3 months (if 
the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for 
persons aged 13 years and older, the minimum interval between doses is 4 weeks.
11. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)
Ro tine vaccination:
•	 Initiate the 2- ose HepA vaccine series at 12 through 23 months; separate the 2 doses by 6 to 18 months.
•	 Children who have received 1 dose of HepA va cine before ge 24 months should receive a second dose 
6 to 18 months after the first dose.
•	 For any p rson aged 2 year  and older who has not already r ceived the HepA vaccine series, 2 do es of 
H pA vaccine separated by 6 to 18 month  may be administered if immunity against hep titis A virus 
infection is desired. 
Catch-up vaccination:
•	 The minimum interval between the two doses is 6 months. 
Special populations: 
•	 Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who 
live in areas wher  vac ination programs t rget older children, or who are at increased risk for infection.  
This includes persons traveling to or working in countries that have high or intermediate endemicity of 
infection; men having sex with men; users of injection and non-inje tion illicit drugs; persons who work 
with HAV-infected primates or with HAV in  research laboratory; persons with clotting-fact r disorders; 
persons with chronic liver diseas ; and persons who anticipate close p r onal contact (e.g., household 
or regular babysitting) with an international adoptee during the first 60 days after arrival in the United 
States from a country with high or intermediate endemicity. The first dose should be administered as 
soon as the adoption is planned, ideally 2 or more w eks before the arrival of the adoptee.
12. Human papillomavirus (HPV) vaccines.  (Minimum age:  9 years for HPV2 [Cervarix] 
and HPV4 [Gardasil])  
Routine vaccination:
•	 Administer a 3-dose series of HPV vaccine on a schedule of 0, 1-2, and 6 months to all adolescents aged 11 
through 12 years. Either HPV4 or HPV2 may be used for females, and only HPV4 may be used for males.
•	 The vaccine series may be started at age 9 years.
•	 Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks); administer the 
third dose 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of 12 weeks).
Catch-up vaccination:
•	 Administer the vaccine series to females (either HPV2 or HPV4) and males (HPV4) at age 13 through 18 
years if not previously vaccinated.
•	 Use recommended routine dosing intervals (see Routine vaccination above) for vaccine series catch-up. 
13. Meningococcal co jugat  vaccines. (Minimum age: 6 we ks for Hib-MenCY 
[MenHibrix], 9 months for MenACWY-D [Menactra], 2 months for MenACWY-CRM 
[Menveo])
Routine vaccination:
•	 Administer a single dose of Menactra or Menveo vaccine at age 11 through 12 years, with a booster dose 
at age 16 years.
•	 Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV ) infection should 
receive a 2-dose primary series of Menactra or Menveo with at least 8 weeks between doses.
•	 For children aged 2 months through 18 years with high-risk conditions, see below.
Catch-up vaccination:
•	 Administer Menactra or Menveo vaccine at age 13 through 18 years if not previously vaccinated.
•	 If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 
16 through 18 years with a minimum interval of at least 8 weeks between doses.
•	 If the first dose is administered at age 16 years or older, a booster dose is not needed.
•	 For other catch-up guidance, see Figure 2.
Vaccination of persons with high-risk conditions and other persons at increased risk of disease: 
•	 Children with anatomic or functional asplenia (including sickle cell disease):
1. Menveo  
o Children who initiate vaccination at 8 weeks through 6 months: Administer doses at 2, 4, 6, and 12 months 
of age.
o Unvaccinated children 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks 
after the first dose AND after the first birthday.
o Children 24 months and older who have not received a complete series: Administer 2 primary doses at 
least 8 weeks apart.
2. MenHibrix
o Children 6 weeks through 18 months: Administer doses at 2, 4, 6, and 12 through 15 months of age.
o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given 
at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.
3. Menactra
o Children 24 months and older who have not received a complete series: Administer 2 primary doses at 
least 8 weeks apart. If Menactra is administered to a child with asplenia (including sickle cell disease), 
do not administer Menactra until 2 years of age and at least 4 weeks after the completion of all PCV13 
doses.
•	 Children with persistent complement component deficiency:
1. Menveo
o Children who initiate vaccination at 8 weeks through 6 months: Administer doses at 2, 4, 6, and 12 months 
of age.
o Unvaccinated children 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks 
after the first dose AND after the first birthday.
o Children 24 months and older who have not received a complete series: Administer 2 primary doses at 
least 8 weeks apart. 
2. MenHibrix
o Children 6 weeks through 18 months: Administer doses at 2, 4, 6, and 12 through 15 months of age.
o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given 
at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.
3. Menactra
o Children 9 through 23 months: Administer 2 primary doses at least 12 weeks apart.
o Children 24 months and older who have not received a complete series: Administer 2 primary doses at 
least 8 weeks apart.
•	 For children who travel to or reside in countries in which meningococcal disease is hyperendemic or 
epidemic, including countries in the African meningitis belt or the Hajj, administer an age-appropriate 
formulation and series of Menactra or Menveo for protection against serogroups A and W meningococcal 
disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj 
because it does not contain serogroups A or W.
•	 For children at risk during a community outbreak attributable to a vaccine serogroup, administer or 
complete an age- and formulation-appropriate series of MenHibrix, Menactra, or Menveo.
•	 For booster doses among persons with high-risk conditions, refer to MMWR 2013 / 62(RR02);1-22, 
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm.
For other catch-up recommendations for these persons, and complete information on use of 
meningococcal vaccines, including guidance related to vaccination of persons at increased risk of infection, 
see MMWR March 22, 2013 / 62(RR02);1-22, available at http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf.
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F r further guidanc  on the use of the vaccines mentioned below, see: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.
9. Measles, mumps, and rubell  (MMR) vaccin . (Minimum age: 12 months for routine 
vac ination)
Routin  vaccination:
•	 Administer a 2-dose series of MMR vaccine at ges 12 through 15 months and 4 throug  6 years. The 
second dose may be administered before age 4 ye rs, p ovided at least 4 weeks have elapsed since the first 
dose.
•	 Administer 1 dose of MMR vaccine to infants aged 6 through 11 months before departure from the United 
Stat s for international travel. These children should be revaccinated with 2 doses of MMR vacci e, the first 
at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the 
second dose at l ast 4 we ks later.
•	 Administer 2 doses of MMR vaccine to children aged 12 months and older befor  departure from the 
United States for international travel. The first d se should b  administered on or after age 12 months and 
the econd dose at least 4 weeks later.
Catch-up vaccination:
•	 Ensure that all school-aged children an  adolescents have had 2 doses of MMR vaccine; the minimum 
interval between the 2 doses is 4 weeks.  
10. Vari ella (VAR) vaccine. (Minimum age: 12 m nths) 
Routin  vaccination:
•	 Administer a 2-dose series of VAR vaccine at ag s 12 through 15 months and 4 through 6 years. The 
seco ose may be administered b fore ag  4 years, provided at least 3 months have elapsed since the 
firs  dose. If the s cond dose was administered at least 4 weeks after the first dose, it can be accepted as 
valid.
Catch-up vaccination:
•	 Ensure that all persons ag d 7 through 18 years without evidence of immunity (see MMWR 2007 / 56 [No. 
RR-4], available t http://www.cdc.g v/mmwr/pdf/rr/rr5604.pdf ) have 2 doses of varicella vaccin .  For 
c ildren aged 7 through 12 years, the recommended minimum interval betw en doses is 3 months (if 
t e second dose w  administered at least 4 weeks after the first dose, it can be accepted as valid); for 
persons aged 13 years and older, the minimum interval between doses is 4 weeks.
11. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)
Routin  vaccination:
•	 Initiate the 2-dose HepA vaccine series at 12 through 23 months; separate the 2 doses by 6 to 18 months.
•	 Children who have received 1 dose of HepA vaccine before age 24 months should receive a second dose 
6 to 18 months after the first dose.
•	 For any person aged 2 years and older who has not already received the HepA vaccine series, 2 doses of 
HepA vaccine separated by 6 to 18 months may be administered if immunity ag inst hepatitis A virus 
infection is desired. 
Catch-up vaccination:
•	 The minimum interval between the two doses is 6 months. 
Special populations: 
•	 Administer 2 doses of HepA vaccine at least 6 mo ths apart to previously unvaccinated persons who 
live in areas where vaccination programs target older children, or who are at increased risk for infection.  
This includes persons traveli g to or working in countries that h v  high or intermediate ndemicity of 
i fection; men having sex with men; users of injection and non-injection illicit drugs; persons who work 
with HAV-infected primate  or with HAV in a research laboratory; perso s with clotting-factor dis rders; 
persons with chronic liv r disease; and persons wh  ticipate close personal conta t (e.g., household 
or regular babysitting) with an i ter ational ad ptee during the first 60 days after arrival in the United 
States fro  a country with high or i termediat  endemicity. Th  first dos  should be administered as 
soon as the adoption is planned, ideally 2 or more weeks before the arrival of the a op ee.
12. Human papillomavirus (HPV) vaccines.  (Minimum age:  9 years for HPV2 [Cervarix] 
and HPV4 [Gardasil])  
Routine vaccination:
•	 Administer a 3-dose series of HPV vaccine on a schedule of 0, 1-2, and 6 months to all adolescents aged 11 
through 12 years. Either HPV4 or HPV2 may be used for females, and only HPV4 may be used for males.
•	 The vaccine series may be started at age 9 years.
•	 Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks); administer the 
third dose 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of 12 weeks).
Catch-up vaccination:
•	 Administer the vaccine series to females (either HPV2 or HPV4) and males (HPV4) at age 13 through 18 
years if not previously vaccinated.
•	 Use recommended routine dosing intervals (see Routine vaccination above) for vaccine series ca ch-up. 
13. Meningococcal conjugate vaccines. (Minimum age: 6 weeks for Hib-MenCY 
[MenHibrix], 9 months for MenACWY-D [Menactra], 2 months for MenACWY-CRM 
[Menveo])
Routin  vaccination:
•	 Administer a single dose of Menactra or Menveo vaccine at age 11 through 12 years, with a booster dose 
at age 16 years.
•	 Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV ) infection should 
receive a 2-dose primary series of Menactra or Menveo with at least 8 weeks between doses.
•	 For children aged 2 months through 18 years with high-risk conditions, see below.
Catch-up vaccination:
•	 Administer Menactra or Menveo vaccine at age 13 through 18 years if not previously vaccinated.
•	 If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 
16 through 18 years with a minimum interval of at least 8 weeks between doses.
•	 If the first dose is administered at age 16 years or older, a booster dose is not needed.
•	 For other catch-up guidance, see Figure 2.
Vaccination of persons with high-risk conditions and other persons at increased risk of disease: 
•	 Children with anatomic or functional asplenia (including sickle cell disease):
1. Menveo  
o Children who initiate vaccination at 8 weeks through 6 months: Administer doses at 2, 4, 6, and 12 months 
of age.
o Unvaccinated children 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks 
after the first dose AND after the first birthday.
o Children 24 months and older who have not received a c mplet  series: Administer 2 primary doses at 
least 8 weeks apart.
2. MenHibrix
o Children 6 weeks through 18 months: Administer doses at 2, 4, 6, and 12 through 15 months of age.
o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given 
at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.
3. Menactra
o Children 24 months and older who have not received a complete series: Administer 2 primary doses at 
least 8 weeks apart. If Menactra is administered to a child with asplenia (including sickle cell disease), 
do not administer Menactra until 2 years of age and at least 4 weeks after the completion of all PCV13 
doses.
•	 Children with persistent complement component deficiency:
1. Menveo
o Children who initiate vaccination at 8 weeks through 6 months: Administer doses at 2, 4, 6, and 12 months 
of age.
o Unvaccinated children 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks 
after the first dose AND after the first birthday.
o Children 24 months and older who have not received a complete series: Administer 2 primary doses at 
least 8 weeks apart. 
2. MenHibrix
o Children 6 weeks through 18 months: Administer doses at 2, 4, 6, and 12 through 15 months of age.
o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given 
at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.
3. Menactra
o Children 9 through 23 months: Administer 2 primary doses at least 12 weeks apart.
o Children 24 months and older who have not received a complete series: Administer 2 primary doses at 
least 8 weeks apart.
•	 For children who travel to or reside in countries in which meningococcal disease is hyperendemic or 
epidemic, including countries in the African meningitis belt or the Hajj, administer an age-appropriate 
formulation and series of Menactra or Menveo for protection against serogroups A and W meningococcal 
disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj 
because it does not contain serogroups A or W.
•	 For children at risk during a community outbreak attributable to a vaccine serogroup, administer or 
complete an age- and formulation-appropriate series of MenHibrix, Menactra, or Menveo.
•	 For booster doses among persons with high-risk conditions, refer to MMWR 2013 / 62(RR02);1-22, 
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm.
For other catch-up recommendations for these persons, and complete information on use of 
meningococcal vaccines, including guidance related to vaccination of persons at increased risk of infection, 
s e MWR March 22, 2013 / 62(RR02);1-22, avail bl  at http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf.
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